Navigation Links
Genta Restructures Operations to Focus on Priority Initiatives
Date:4/2/2008

Company to Seek Buyer for Marketed Product Ganite(R) Lloyd Sanders Assumes Chief Operating Officer Role in Consolidated Company

BERKELEY HEIGHTS, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced that the Company has restructured certain of its operations to conserve cash and focus on its priority oncology development operations. In March 2008, the Company received notice that its appeal of an adverse decision by the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) regarding its New Drug Application (NDA) for the use of Genasense(R) in patients with chronic lymphocytic leukemia (CLL) would not be reversed. While the Company is undertaking certain actions recommended by CDER, this decision precludes a commercial launch of Genasense during 2008, and accordingly the Company has reduced its workforce by 16 people, or approximately 30%.

"The highest priority for the Company is the timely completion of accrual and data readout from AGENDA, our ongoing Phase 3 trial of Genasense in patients with advanced melanoma", said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Since these products address important patient needs and generate revenue for the Company, we will be maintaining our "named-patient" programs for Genasense and Ganite. However, given the delays in commercialization of our lead product, we have underinvested in our marketed drug, Ganite(R), and will be seeking buyers for that product. In other actions, we expect to file a complete response to FDA's clinical hold on tesetaxel, our new oral taxane, and we anticipate clinical presentations on both Genasense and G4544 -- an oral compound that reduces calciu
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... ... 530 sample changer for vials can be used with Anton Paar density meters, viscometers ... mPas (internal air) up to 36,000 (external air) – and can process up to 71 ... is its removable magazine, which is easily lifted off its hub and carried by hand ...
(Date:7/28/2015)... , July 21, 2015 ... has announced the addition of the "Analysis ... report to their offering. Globally, flow ... including immuno-phenotyping, cell proliferation, cancer, and stem cells. ... clinical applications primarily because of demand from underdeveloped ...
(Date:7/28/2015)... DIEGO , July 28, 2015  Kerastem Technologies ... approval from the U.S. FDA Center For Biologics Evaluation ... Therapies to conduct a clinical trial investigating the safety ... of female and early male pattern baldness (androgenic alopecia). ... STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results for ... "Orenitram ®  sales grew nearly 300% as compared ... product was first launched," said Roger Jeffs, Ph.D., ... growth in Orenitram sales was due to an ...
Breaking Biology Technology:New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Business Conference, an MBA-student organized event, will be held February 19-20 ... and panelists from Healthcare Services, Investment, Pharma, Biotech, and Medical Device ... ... -- The 2009 Wharton Health Care Business Conference , an ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
... nanotubes close to their breaking point, researchers at ... increase in the current-carrying capacity of the nanotubes, ... researchers drove semiconducting carbon nanotubes into an avalanche ... similar to the way a multilane highway carries ...
Cached Biology Technology:14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5Carbon nanotube avalanche process nearly doubles current 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Rochelle, NY, March 12, 2013The foodborne bacteria Listeria ... each year and many more worldwide, killing about 25-30% ... contaminated with L. monocytogenes , and current methods ... An innovative nanotechnology-based method for developing an inexpensive biosensor ...
... the world,s most commonly used human cell lines, and ... biological processes. In a study published today in ... the European Molecular Biology Laboratory in Heidelberg, announce they ... line. It provides a high-resolution genomic reference that reveals ...
... new study by researchers at the University of Arizona and ... can predict heat stress in cows. In a presentation ... Meeting, Dr. Jamison Allen explained that predicting heat stress is ... eat less and produce less milk when their core body ...
Cached Biology News:Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 3Havoc in biology's most-used human cell line 2Heat-stressed cows spend more time standing 2
... to JAK2 (phospho Y1007) ( Abpromise ... Antigen: Synthesized phosphopeptide ... phosphorylation site of tyrosine 1007 (K-E-Y ... Gene ID: 3717 ...
... Perm Buffer III ... following fixation of PBMCs ... for staining for intracellular ... markers simultaneously. Applications: ...
Cytofix/Cytoperm Kit 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: